Real time, noninvasive imaging and quantitation of the accumulation of ligand-targeted drugs into receptor-expressing solid tumors

Molecular Pharmaceutics

Volumn 6, Issue 6, 2009, Pages 1868-1875

  Vlashi, Erina ^a   Sturgis, Jennifer E ^a   Thomas, Mini ^a   Low, Philip S ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Folic acid; Real time imaging; Targeted cancer therapy; Tumor uptake

Indexed keywords

FOLATE RECEPTOR; FOLIC ACID; HOE 33342; RHODAMINE B;

AMINE TRANSPORT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG TARGETING; IN VIVO STUDY; MOLECULAR WEIGHT; MOUSE; MULTIPHOTON MICROSCOPY; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SOLID TUMOR;

ANIMALS; CARRIER PROTEINS; FOLIC ACID; KINETICS; MICE; MICE, NUDE; NEOPLASMS; RECEPTORS, CELL SURFACE; RHODAMINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 71949089489     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900158d     Document Type: Article

References (48)

1. Ross, J. S.; Schenkein, D. P.; Pietrusko, R.; et al. Targeted therapies for cancer 2004. Am. J. Clin. Pathol. 2004, 122, 598-609.
2. Arslan, M. A.; Kutuk, O.; Basaga, H. Protein kinases as drug targets in cancer. Curr. Cancer Drug Targets 2006, 6, 623-634 (Pubitemid 44691004)
3. Mauro, M. J.; Druker, B. J. STI571: a gene product-targeted therapy for leukemia. Curr. Oncol. Rep. 2001, 3, 223-227
4. Kirby, A. M.; A'Hern, R. P.; D'Ambrosio, C.; et al. Gefitinib (ZD1839, Iressatrade mark) as palliative treatment in recurrent or metastatic head and neck cancer. Br. J. Cancer 2006.
5. Blackhall, F. H.; Rehman, S.; Thatcher, N. Erlotinib in non-small cell lung cancer: a review. Expert Opin. Pharmacother. 2005, 6, 995-1002. (Pubitemid 40946160)
6. Arnould, L.; Gelly, M.; Penault-Llorca, F.; et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism. Br. J. Cancer 2006, 94, 259-267
7. Romond, E. H.; Perez, E. A.; Bryant, J.; et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005, 353, 1673-1684 (Pubitemid 41464706)
8. Blagosklonny, M. V. How avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy. Cancer Biol. Ther. 2005, 4, 1307-1310
9. Gasparini, G.; Longo, R.; Toi, M.; Ferrara, N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat. Clin. Pract. Oncol. 2005, 2, 562-577 (Pubitemid 41721816)
10. Sievers, E. L.; Linenberger, M. Mylotarg: antibody-targeted chemotherapy comes of age. Curr. Opin. Oncol. 2001, 13, 522-527
11. Kawakami, K.; Nakajima, O.; Morishita, R.; Nagai, R. Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties. TheScientificWorld 2006, 6, 781-790
12. Kreitman, R. J.; Pastan, I. Targeting Pseudomonas exotoxin to hematologic malignancies. Semin. Cancer Biol. 1995, 6, 297-306.
13. Dreher, M. R.; Liu, W.; Michelich, C. R.; Dewhirst, M. W.; Yuan, F.; Chilkoti, A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl. Cancer Inst. 2006, 98, 335-344 (Pubitemid 43338213)
14. Leamon, C. P.; Low, P. S. Selective targeting of malignant cells with cytotoxin-folate conjugates. J. Drug Targeting 1994, 2, 101-112 (Pubitemid 24194288)
15. Ross, J. F.; Chaudhuri, P. K.; Ratnam, M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994, 73, 2432-2443 (Pubitemid 24129130)
16. Toffoli, G.; Cernigoi, C.; Russo, A.; Gallo, A.; Bagnoli, M.; Boiocchi, M. Overexpression of folate binding protein in ovarian cancers. Int. J. Cancer 1997, 74, 193-198 (Pubitemid 27234510)
17. Lu, Y.; Sega, E.; Leamon, C. P.; Low, P. S. Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Adv. Drug Delivery Rev. 2004, 56, 1161-1176 (Pubitemid 38496513)
18. Hilgenbrink, A. R.; Low, P. S. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J. Pharm. Sci. 2005, 94, 2135-2146 (Pubitemid 41665275)
19. Huennekens, F. M.; DiGirolamo, P. M.; Fujii, K.; Jacobsen, D. W.; Vitols, K. S. B12 - dependent methionine synthetase as a potential target for cancer chemotherapy. Adv. Enzyme Regul. 1976, 14, 187-205.
20. Bagnato, J. D.; Eilers, A. L.; Horton, R. A.; Grissom, C. B. Synthesis and characterization of a cobalamin-colchicine conjugate as a novel tumor-targeted cytotoxin. J. Org. Chem. 2004, 69, 8987-8996 (Pubitemid 40004017)
21. Stangelberger, A.; Schally, A. V.; Letsch, M.; et al. Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers. Int. J. Cancer 2006, 118, 222-229
22. Szepeshazi, K.; Schally, A. V.; Nagy, A.; Halmos, G. Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog. Pancreas 2005, 31, 275-282 (Pubitemid 41400486)
23. Nagy, A.; Schally, A. V. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy. Curr. Pharm. Des. 2005, 11, 1167-1180
24. Dharap, S. S.; Wang, Y.; Chandna, P.; et al. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 12962-12967
25. Eaveri, R.; Ben-Yehudah, A.; Lorberboum-Galski, H. Surface antigens/receptors for targeted cancer treatment: the GnRH receptor/binding site for targeted adenocarcinoma therapy. Curr. Cancer Drug Targets 2004, 4, 673-687 (Pubitemid 40013573)
26. Ben-Yehudah, A.; Lorberboum-Galski, H. Targeted cancer therapy with gonadotropin-releasing hormone chimeric proteins. Expert Rev. Anticancer Ther. 2004, 4, 151-161 (Pubitemid 38208494)
27. Ahmed, A. E.; Jacob, S.; Giovanella, B. C.; Kozielski, A. J.; Stehlin, J. S., Jr.; Liehr, J. G. Influence of route of administration on [3H]-camptothecin distribution and tumor uptake in CASE-bearing nude mice: whole-body autoradiographic studies. Cancer Chemother. Pharmacol. 1996, 39, 122-130
28. Noy, R.; Ben-Zvi, Z.; Elezra, M.; et al. Pharmacokinetics and organ distribution of N-methanocarbathymidine, a novel thymidine analog, in mice bearing tumors transduced with the herpes simplex thymidine kinase gene. Cancer Chemother. Pharmacol. 2002, 50, 360-366
29. Harivardhan Reddy, L.; Sharma, R. K.; Chuttani, K.; Mishra, A. K.; Murthy, R. S. Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J. Controlled Release 2005, 105, 185-198
30. Minchinton, A. I.; Tannock, I. F. Drug penetration in solid tumours. Nat. Rev. Cancer 2006, 6, 583-592
31. Fujimori, K.; Covell, D. G.; Fletcher, J. E.; Weinstein, J. N. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J. Nucl. Med. 1990, 31, 1191-1198
32. Juweid, M.; Neumann, R.; Paik, C.; et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 1992, 52, 5144-5153
33. Weinstein, J. N.; van Osdol, W. Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier". Cancer Res. 1992, 52, 2747s-51s.
34. Saga, T.; Neumann, R. D.; Heya, T.; et al. Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 8999-9003.
35. Campbell, I. G.; Jones, T. A.; Foulkes, W. D.; Trowsdale, J. Folate-binding protein is a marker for ovarian cancer. Cancer Res. 1991, 51, 5329-5338
36. Weitman, S. D.; Lark, R. H.; Coney, L. R.; et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 1992, 52, 3396-3401
37. Wu, M.; Gunning, W.; Ratnam, M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol. Biomarkers Prev. 1999, 8, 775-782 (Pubitemid 29445014)
38. Parker, N.; Turk, M. J.; Westrick, E.; Lewis, J. D.; Low, P. S.; Leamon, C. P. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem. 2005, 338, 284-293
39. Luo, J. S. M.; Lantrip, D. A.; Wang, S.; Fuchs, P. L. Efficient syntheses of pyrofolic acid and pteroyl azide, reagents for the production of carboxyl-differentiated derivatives of folic acid. J. Am. Chem. Soc. 1997, 119, 10004-10013
40. Henne, W. A.; Doorneweerd, D. D.; Hilgenbrink, A. R.; Kularatne, S. A.; Low, P. S. Synthesis and activity of a folate peptide camptothecin prodrug. Bioorg. Med. Chem. Lett. 2006, 16, 5350-5355
41. Mathias, C. J.; Wang, S.; Lee, R. J.; Waters, D. J.; Low, P. S.; Green, M. A. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J. Nucl. Med. 1996, 37, 1003-1008
42. van Osdol, W.; Fujimori, K.; Weinstein, J. N. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier". Cancer Res. 1991, 51, 4776-4784
43. Graff, C. P.; Wittrup, K. D. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 2003, 63, 1288-1296
44. Kennel, S. J. Effects of target antigen competition on distribution of monoclonal antibody to solid tumors. Cancer Res. 1992, 52, 1284-1290
45. Scopinaro, F.; Di Santo, G. P.; Tofani, A.; et al. Fast cancer uptake of 99mTc-labelled bombesin (99mTc BN1). In vivo 2005, 19, 1071-1076
46. Leamon, C. P.; Reddy, J. A.; Vlahov, I. R.; et al. Synthesis and biological evaluation of EC72: a new folate-targeted chemotherapeutic. Bioconjugate Chem. 2005, 16, 803-811 (Pubitemid 41026166)
47. Vlahov, I. R.; Santhapuram, H. K.; Kleindl, P. J.; Howard, S. J.; Stanford, K. M.; Leamon, C. P. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg. Med. Chem. Lett. 2006, 16, 5093-5096
48. Brown, E.; McKee, T.; diTomaso, E.; et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat. Med. 2003, 9, 796-800.